A fact-checked conducted by The New York Times and CNBC confirms that remdesvir, which was being developed to fight Ebola is being tested in COVID-19.
Six studies are in progress, with the first, in severely ill patients in China, due to finish as early as April 3, 2020. A study in patients with the milder disease will also finish in April, with two more due in May. Gilead had made the drug available to hundreds of patients on a compassionate use basis. However, it recently said that, due to overwhelming demand, it would suspend access to the drug for all but pregnant women and children as it works to create a more systematic way of giving it out without interfering with clinical trials.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.